Edwards Lifesciences Corporation's (EW) CEO Mike Mussallem on Q1 2021 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q1: 2021-04-20 Earnings Summary

EPS of $0.54 beats by $0.07
 | Revenue of $1.22B (7.79% Y/Y) beats by $53.38M

Edwards Lifesciences Corporation (NYSE:EW) Q1 2021 Earnings Conference Call April 20, 2021 5:30 PM ET

Company Participants

Mark Wilterding - President, Investor Relations
Mike Mussallem - Chairman and CEO
Scott Ullem - CFO

Conference Call Participants

Bob Hopkins - Bank of America
Robert Marcus - JPMorgan
Vijay Kumar - Evercore ISI
Larry Biegelsen - Wells Fargo
Joshua Jennings - Cowen and Company
Cecilia Furlong - Morgan Stanley
Matt Miksic - Credit Suisse
Joanne Wuensch - Citigroup
Danielle Antalffy - SVB Leerink
Anthony Petrone - Jefferies
Adam Maeder - Piper Sandler
Matt Taylor - UBS
Pito Chickering - Deutsche Bank
Jayson Bedford - Raymond James

Operator

Greetings, and welcome to the Edwards Lifesciences First Quarter 2021 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note that this conference is being recorded.

I will now turn the conference over to our host, Mark Wilterding, Vice President of Investor Relations. Thank you. You may begin.

Mark Wilterding

Thank you, Diego. Good afternoon, and thank you for joining us. With me on today's call are Mike Mussallem, Chairman and Chief Executive Officer; and Scott Ullem, Chief Financial Officer. Just after the close of regular trading, Edwards Lifesciences released first quarter 2021 financial results. During today's call, management will discuss those results included in the press release and accompanying financial statements and then use the remaining time for Q&A.

Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to: financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations. These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve

Recommended For You

About EW Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on EW